Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

597.78 -1.57 (-0.26%)
Streaming Delayed Price Updated: 9:43 AM EST, Nov 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Argenx Se ADR

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Micron Therapies Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Shares of Micron Technology, Inc. (NASDAQ: MU) rose sharply in today’s pre-market trading as the company reported upbeat results for its second quarter and issued 
Via Benzinga
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
From argenx SE
Via GlobeNewswire
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Why Is Argenx (ARGX) Stock Down 25% Today?
Following a late-stage clinical disappointment, Argenx has been forced back to the drawing board, thus cratering ARGX stock. 
Via InvestorPlace
Argenx Dives On Autoimmune Therapy Failure
A treatment for a skin-blistering condition failed to beat a placebo. 
Via Investor's Business Daily
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
From argenx SE
Via GlobeNewswire
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials. 
Via InvestorPlace
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
5 medical stocks growing earnings by triple digits
There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning 
Via MarketBeat
Topics Economy
Exposures Economy
New Hope For Patients With Chronic Autoimmune Conditions: Johnson & Johnson's Investigational Drug Meets Primary Goal In Two Studies
Johnson & Johnson's nipocalimab shows promise in Phase 3 VIVACITY for gMG & Phase 2 DAHLIAS for SjD. FDA-approved Vyvgart Hytrulo for gMG. 
Via Benzinga
Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion
Explore Halozyme Therapeutics' promising financial outlook up to 2028. Discover revenue forecasts, earnings projections, and market insights. 
Via Benzinga
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
These five biotech companies could have a lot of room to run. 
Via The Motley Fool
argenx Highlights 2024 Strategic Priorities
From argenx SE
Via GlobeNewswire
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
Despite a Wednesday tumble, the major indexes are right at 2023 highs. 
Via Investor's Business Daily
Argenx's Autoimmune Trial Stumble: Analysts Cut Price Targets, Warn of Risky Outcomes
Wednesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADDRESS Phase 3 study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with pemphigus... 
Via Benzinga
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
Immunovant reversed its fortunes Thursday following an Argenx-tied selloff Wednesday. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Is European Drugmaker Argenx Stock Sinking Today?
Argenx SE (NASDAQ: ARGX) shares plunged after the company released topline results from the ADDRESS Phase 3 study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in... 
Via Benzinga
Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
Shares of Aclarion, Inc. (NASDAQ: ACON) shares rose sharply in pre-market trading after the company was granted U.S. patent #11844601 for "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.